Ellie Leick

Articles

Promising PARP Inhibitor Strategies Emerging in Platinum-Sensitive Ovarian Cancer

July 24th 2019

Richard T. Penson, MD, MRCP, discusses novel strategies with PARP inhibitors and the use of biomarkers to create more personalized treatments for patients with platinum-sensitive ovarian cancer.

Expert Explains Evolution of De-Escalating Therapies in HER2+ Breast Cancer

July 19th 2019

Keerthi Gogineni, MD, MSHP, discusses several trials in the breast cancer field, specifically looking at de-escalation therapies.

Molecular Testing Continues to Evolve in Ovarian Cancer

July 19th 2019

Jubilee Brown, MD, discusses the importance of molecular testing immediately after an ovarian cancer diagnosis and how molecular testing will shape the field of ovarian cancer.

SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis

July 17th 2019

Thomas Herzog, MD, discusses recent changes in the ovarian cancer landscape, specifically PARP inhibitors and the optimal use of bevacizumab.

Expert Highlights Need for Widespread Liquid Biopsy Use in Lung Cancer Treatment

July 15th 2019

Alain Borczuk, MD, discusses the recent advancements in lung cancer treatment, the evolving field, and the future potential for liquid biopsies.

Gainor Highlights Future of Immunotherapy in Stage III Lung Cancer Treatment

July 14th 2019

Justin F. Gainor, MD, highlights the evolving paradigm for the use of immunotherapy in the treatment of patients with unresectable locally advanced non–small cell lung cancer.

Enzalutamide Could Have Pivotal Role in Metastatic Hormone-Sensitive Prostate Cancer

July 12th 2019

Christopher Sweeney, MBBS, discusses the results of the ENZAMET trial and the next steps for researching the efficacy of enzalutamide in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Immunotherapy Research Continues to Emerge in Urothelial Cancer

July 12th 2019

Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.

Efforts Continue to Increase Lung Cancer Screening

July 11th 2019

Inga T. Lennes, MD, MBA, MPH, discusses the recommended screening protocol for patients at risk for lung cancer, maintaining patients post-screening, and how physicians can best assist this patient population.

Studies Continue to Evaluate Potential With Pemetrexed in NSCLC

July 10th 2019

Mary Jo J. Fidler, MD, discusses intriguing data with pemetrexed in patients with nonsquamous non–small cell lung cancer.

Therapeutic Developments in AML Lead to Sequencing Questions

July 3rd 2019

Robert L. Redner, MD, highlights some of the newer available agents in acute myeloid leukemia and ongoing studies that could impact clinical practice.

Entrectinib Shows Real-World PFS Benefit in ROS1+ NSCLC

July 3rd 2019

Robert C. Doebele, MD, PhD, discusses a retrospective trial comparing the efficacy of entrectinib with crizotinib in the treatment of patients with ROS1-positive non–small cell lung cancer.

Cowan Highlights Practice-Changing Combo Regimens in Multiple Myeloma

July 3rd 2019

Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.

Lead Investigator Highlights Apalutamide Efficacy in Metastatic Castration-Sensitive Prostate Cancer

July 1st 2019

Kim Chi, MD, discusses how the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy could be a new standard of care for patients with metastatic castration-sensitive prostate cancer.

Maintenance Pembrolizumab Extends PFS in Metastatic Urothelial Cancer

June 27th 2019

Switch maintenance treatment with pembrolizumab improved progression-free survival in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy.

Borghaei Discusses Long-Term Pembrolizumab NSCLC Data, Broadening Clinical Trial Eligibility

June 26th 2019

Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.

Woyach Highlights Long-Term Acalabrutinib/Obinutuzumab Data in CLL

June 26th 2019

Jennifer Woyach, MD, discusses the 3-year follow-up from the single-arm study of the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia and the future of treatment in the space.

Surgery Shows Potential Survival Benefit in Metastatic HER2+ Breast Cancer

June 25th 2019

Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.

Brown Highlights the Future of Acalabrutinib in CLL Treatment

June 20th 2019

Jennifer R. Brown, MD, PhD, highlights the new and upcoming research regarding acalabrutinib in the field of chronic lymphocytic leukemia.

Cost of Treatments Tops Survey of Oncologists' Concerns

February 21st 2017

Concern over the cost of cancer drugs nearly doubled among oncology professionals from 2015 to 2016, jumping from 45% to 83%.